The estimated Net Worth of Uri A Lopatin is at least 11.3 百万$ dollars as of 5 September 2018. Dr Lopatin owns over 15,540 units of Assembly Biosciences Inc stock worth over 10,664,559$ and over the last 8 years he sold ASMB stock worth over 622,999$.
Dr has made over 1 trades of the Assembly Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 15,540 units of ASMB stock worth 622,999$ on 5 September 2018.
The largest trade he's ever made was selling 15,540 units of Assembly Biosciences Inc stock on 5 September 2018 worth over 622,999$. On average, Dr trades about 3,885 units every 0 days since 2017. As of 5 September 2018 he still owns at least 613,611 units of Assembly Biosciences Inc stock.
You can see the complete history of Dr Lopatin stock trades at the bottom of the page.
Dr. Uri A. Lopatin M.D. is the Co-Founder and Clinical & Scientific Advisor at Assembly Biosciences Inc.
Dr D is 49, he's been the Co-Founder and Clinical & Scientific Advisor of Assembly Biosciences Inc since . There are 12 older and 5 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
Uri's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL, IN, 46032.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over 1,523,622$ worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth 1,060,065$ . The most active insiders traders include Sciences, Inc. Gilead、Myron Z Holubiak、Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of 389,399$. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth 11,171$.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: